← All indications
Immune Checkpoint Inhibitors
Drugs that block negative regulator IMMUNE CHECKPOINT proteins (e.g., PD-1 RECEPTOR and CTLA-4 ANTIGEN) thereby increasing suppressed immune activation in immunotherapies.
Drugs by status
Phase 3 trials (15)
Phase 2 trials (37)
- axitinib
- anlotinib
- atezolizumab
- lenalidomide
- prednisone
- fruquintinib
- fluorouracil
- paclitaxel
- tenofovir
- Filgrastim
- nivolumab
- pembrolizumab
- leucovorin
- regorafenib
- osimertinib
- pemetrexed
- sunitinib
- carboplatin
- rc48-adc
- celecoxib
- belimumab
- bevacizumab
- dendritic cells
- antigen pulsed dendritic cells
- docetaxel
- asparaginase
- xelox
- relatlimab
- toripalimab
- chidamide
- +7 more
Phase 1 trials (1)
Other trials (1)